Emerging Role of Atopic Dermatitis Control Tool in Long-Term Monitoring of Patients With Moderate-to-Severe Atopic Dermatitis Treated With Dupilumab

Dermatitis. 2024 Jan-Feb;35(S1):S107-S108. doi: 10.1089/derm.2023.0052. Epub 2023 Aug 18.

Authors

Vittoria Cioppa¹, Laura Lazzeri¹, Andrea Carraro¹, Ernesto De Piano¹, Francesca Falcinelli¹, Marco Galluzzo², Sabatino Pallotta³, Ornella De Pità³, Filomena Russo³

Affiliations

¹ Dermatology Section, Department of Medical, Surgical and Neurological Science, University of Siena, S. Maria alle Scotte Hospital, Siena, Italy.
² Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy.
³ Dermatological Research Hospital, IDI-IRCCS, Rome, Italy.

PMID: 37594754
DOI: 10.1089/derm.2023.0052

No abstract available

MeSH terms

Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal, Humanized / therapeutic use
Dermatitis, Atopic* / chemically induced
Dermatitis, Atopic* / drug therapy
Double-Blind Method
Humans
Severity of Illness Index
Treatment Outcome

Substances

dupilumab
Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal